In a murine model of triple-negative breast cancer with lung metastasis, palmatine (1, 5, and 10 mg/kg) demonstrated dose-dependent therapeutic efficacy by significantly ameliorating metastatic lung injury and hypoxemia, downregulating metastasis-associated protein 1 (MTA1), while upregulating the expression of the tumor suppressor p53, thereby preserving pulmonary histomorphology (Ativui et al., 2022). The gene discussed is MTA1; the disease is triple-negative breast carcinoma.